Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
3.25 USD +2.52% Intraday chart for Leap Therapeutics, Inc. +16.07% -21.59%
04-10 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
03-19 Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Number of employees: 54

Managers

Managers TitleAgeSince
Doug Onsi CEO
 Chief Executive Officer 55 31/12/10
Chris Mirabelli CHM
 Chairman 69 31/12/10
Jason Baum CTO
 Chief Tech/Sci/R&D Officer 45 23/08/20
Michael Haas CTO
 Chief Tech/Sci/R&D Officer - -
Cynthia Sirard CTO
 Chief Tech/Sci/R&D Officer 54 31/12/11
Augustine Lawlor COO
 Chief Operating Officer 67 31/12/15
Christine M. Granfield LAW
 General Counsel 56 23/08/20
Jonathan Miller PRN
 Corporate Officer/Principal - 31/12/19
Mark O’Mahony PRN
 Corporate Officer/Principal 53 31/12/10

Members of the board

Members of the board TitleAgeSince
Joseph Loscalzo BRD
 Director/Board Member 72 31/12/15
Nissim Mashiach BRD
 Director/Board Member 63 31/12/16
Chris Mirabelli CHM
 Chairman 69 31/12/10
James Cavanaugh BRD
 Director/Board Member 87 31/12/15
Thomas Dietz BRD
 Director/Board Member 60 31/12/15
Doug Onsi CEO
 Chief Executive Officer 55 31/12/10
Chris Richard BRD
 Director/Board Member 54 16/01/23
Patricia Martin BRD
 Director/Board Member 63 31/12/22
Richard Schilsky BRD
 Director/Board Member 73 31/08/22
William Li BRD
 Director/Board Member 61 31/12/16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,261,130 32,139,737 ( 84.00 %) 0 84.00 %

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
20.78 %
5,319,148 20.78 % 14 M $
Samsara Biocapital LLC
9.540 %
2,442,352 9.540 % 6 M $
Baker Bros. Advisors LP
4.579 %
1,172,175 4.579 % 3 M $
Adage Capital Partners GP LLC
3.683 %
942,918 3.683 % 3 M $
Rock Springs Capital Management LP
3.254 %
832,937 3.254 % 2 M $
BEIGENE LTD
2.870 %
734,844 2.870 % 2 M $
Citadel Securities GP LLC
2.667 %
682,749 2.667 % 2 M $
HealthCare Ventures LLC
2.642 %
676,321 2.642 % 2 M $
683 Capital Management LLC
1.758 %
450,000 1.758 % 1 M $
Vanguard Global Advisers LLC
1.601 %
409,804 1.601 % 1 M $

Company contact information

Leap Therapeutics, Inc.

47 Thorndike Street Suite B1-1

02141, Cambridge

+617 714 0360

http://www.leaptx.com
address Leap Therapeutics, Inc.(LPTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.25 USD
Average target price
11.75 USD
Spread / Average Target
+261.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEAP THERAPEUTICS, INC. Stock Leap Therapeutics, Inc.
-21.59% 83.21M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. Company Leap Therapeutics, Inc.